Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 439

Thsi is a year old. But at 27 minutes David gets asked a couple fo “when” questions.

Dr. David Sinclair presents the progress of epigenetic reprogramming and rejuvenation in this video. He’s also answering questions on when he thinks the rejuvenation therapy be available in the Q\&A session at the end of the presentation.

00:54 Presentation.
25:42 Q\&A

David Sinclair is a professor in the Department of Genetics and co-director of the Paul F. Glenn Center for the Biology of Aging at Harvard Medical School, where he and his colleagues study sirtuins—protein-modifying enzymes that respond to changing NAD+ levels and to caloric restriction—as well as chromatin, energy metabolism, mitochondria, learning and memory, neurodegeneration, cancer, and cellular reprogramming.

Dr David Sinclair has suggested that aging is a disease—and that we may soon have the tools to put it into remission—and he has called for greater international attention to the social, economic and political and benefits of a world in which billions of people can live much longer and much healthier lives.

Continue reading “Will Rejuvenation Therapy Be Available In Our LIFETIME? Gene Therapy VS Small Molecules” | >

Years ago, a man paralyzed in a surfing accident was able to walk again after undergoing a revolutionary stem cell treatment. Now, he says that his mobility has only continued to improve! Chris Barr was one out of only 10 people to undergo this experimental treatment in a study by the Mayo Clinic. It’s safe to say that the procedure was a success for this patient!

“I never dreamed I would have a recovery like this,” Chris said, according to Good Morning America.

Before receiving care, Chris was paralyzed from the neck down, making it unlikely that he would ever walk again. However, a new stem cell treatment from the Mayo Clinic offered hope. He would be the first to try it, with incredible results.

Read more | >

Human history was forever changed with the discovery of antibiotics in 1928. Infectious diseases such as pneumonia, tuberculosis and sepsis were widespread and lethal until penicillin made them treatable.

Surgical procedures that once came with a high risk of infection became safer and more routine. Antibiotics marked a triumphant moment in science that transformed medical practice and saved countless lives.

But antibiotics have an inherent caveat: When overused, bacteria can evolve resistance to these drugs. The World Health Organization estimated that these superbugs caused 1.27 million deaths around the world in 2019 and will likely become an increasing threat to global public health in the coming years.

Read more | >

Jason Matheny is a delight to speak with, provided you’re up for a lengthy conversation about potential technological and biomedical catastrophe.

Now CEO and president of Rand Corporation, Matheny has built a career out of thinking about such gloomy scenarios. An economist by training with a focus on public health, he dived into the worlds of pharmaceutical development and cultivated meat before turning his attention to national security.

As director of Intelligence Advanced Research Projects Activity, the US intelligence community’s research agency, he pushed for more attention to the dangers of biological weapons and badly designed artificial intelligence. In 2021, Matheny was tapped to be President Biden’s senior adviser on technology and national security issues. And then, in July of last year, he became CEO and president of Rand, the oldest nonprofit think tank in the US, which has shaped government policy on nuclear strategy, the Vietnam War, and the development of the internet.

Read more | >

National clinical guidelines for the treatment of COVID-19 vary significantly around the world, with under-resourced countries the most likely to diverge from gold standard (World Health Organization; WHO) treatment recommendations, finds a comparative analysis published in the open access journal BMJ Global Health.

And nearly every recommends at least one treatment proven not to work, the analysis shows.

Significant variations in national COVID-19 have been suspected since the advent of the pandemic, but these haven’t been formally quantified or studied in depth, note the researchers.

Read more | >

Rice University engineers have developed the smallest implantable brain stimulator demonstrated in a human patient. Thanks to pioneering magnetoelectric power transfer technology, the pea-sized device developed in the Rice lab of Jacob Robinson in collaboration with Motif Neurotech and clinicians Dr. Sameer Sheth and Dr. Sunil Sheth can be powered wirelessly via an external transmitter and used to stimulate the brain through the dura ⎯ the protective membrane attached to the bottom of the skull.

The device, known as the Digitally programmable Over-brain Therapeutic (DOT), could revolutionize treatment for drug-resistant depression and other psychiatric or neurological disorders by providing a therapeutic alternative that offers greater patient autonomy and accessibility than current neurostimulation-based therapies and is less invasive than other brain-computer interfaces (BCIs).

Read more | >

Advances in gene sequencing technology and computing power have significantly increased the availability of bioinformatic data and processing capabilities. This convergence provides an ideal opportunity for artificial intelligence (AI) to develop methods to control cellular behavior.

In a new study, Northwestern University researchers have reaped fruit from this nexus by developing an AI-powered transfer learning approach that repurposes publicly available data to predict combinations of gene perturbations that can transform cell type or restore diseased cells to health.

The study was recently published in the Proceedings of the National Academy of Sciences.

Read more | >

Generative A.I. technologies can write poetry and computer programs or create images of teddy bears and videos of cartoon characters that look like something from a Hollywood movie.

Now, new A.I. technology is generating blueprints for microscopic biological mechanisms that can edit your DNA, pointing to a future when scientists can battle illness and diseases with even greater precision and speed than they can today.

Read more | >

The process, called primary endosymbiosis, has only happened twice in the history of the Earth, with the first time giving rise to all complex life as we know it through mitochondria. The second time that it happened saw the emergence of plants.

Now, an international team of scientists have observed the evolutionary event happening between a species of algae commonly found in the ocean and a bacterium.

“The first time we think it happened, it gave rise to all complex life,” said Tyler Coale, a postdoctoral researcher at University of California, Santa Cruz, who led the research on one of two recent studies that uncovered the phenomenon.

Read more | >